Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This just means they are looking at acquiring different treatments for their pipeline. I’m not saying there isn’t a chance of an acquisition by BMS but I wouldn’t assume “franchise” is some sort of bread crumb.
dstock07734,
Not forgetting any of that. Just too big of a picture for many to imagine but that is exactly why I said that 3 years from first approval would see such a huge difference in price. The market will really understand better what they are looking at by then even if current longs don’t all hold out for that much bigger valuation that is coming in my opinion. Best wishes.
georgebailey,
The common word of the day between NWBO and BMS… “franchise”. Seems clear enough language to me and addresses the economic balance of power concerns that big pharma has been facing; ). They stay alive as long as they keep pace with NWBO’s market development expansion model with favorably split revenue and entry fees to get to the table. Best wishes.
Doc,
Don't forget about the antiviral field. Take a look at the trials Cytheris SA was running before it was bankrupt and acquired by LP.
Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients (CONVERT)
https://classic.clinicaltrials.gov/ct2/show/NCT01027065
Safety Study of IL-7 in HIV-infected Patients (Inspire)
https://classic.clinicaltrials.gov/ct2/show/NCT00477321
https://www.researchgate.net/publication/24201625_Enhanced_T_cell_recovery_in_HIV-1-infected_adults_through_IL-7_treatment
georgebailey,
…and Edens works with both DCs and T-cells. Talk about being prepared with advanced commercialization of improved product line; ). Best wishes.
dstock07734,
“…discovering IL-7 as the master regulator of T-cell homeostasis”. Now why would the master regulator of T-cell homeostasis have anything to do with the master immune cells of governed immune response (DCs). RevImmune with NWBO using Edens anyone?; ). Best wishes.
"I hope it succeeds."
Wow, I agree with you on this.
renaissance1,
Just waiting on the MHRA decision to be formalized so the unaware and unbelievers can finally become a “woke market” and the paid protagonists are no longer useful. Then big pharma finally has to publicly admit their need of NWBO by making legit offers because of their products being reduced to secondary positions or even unneeded by the DCVax platform with respect to cancer treatment. Best wishes.
dstock07734,
Anyone who underestimates Linda Powers’ ability to use leverage does so at to their own loss or detriment. Your example is just one of many. MHRA vs FDA and PEI being the really big one; ). Best wishes.
Just checking in here. Anything new? Stock has been languishing for awhile. Hoping for some good news soon. Good luck to all.
tryn2,
Just an old fiduciary duty claim against NWBO that was settled for $152,000 without NWBO admitting to legally needing to make changes. Getting all the old litigation cleaned up for the new deals being planned probably. Best wishes.
Big deal. He sold. People buy and people sell. It is life. There is no such thing as a for sure thing. Not even $nwbo. I hope it succeeds. But I also hope it fails to teach pricks like you a lesson.
2017, nothing new
You're the perfect example of my issue with GC advertising his sale.
Case in point
ILT,
GermanCol gave too much credit to EX. Ex is not intellectually equipped to under the whole thing.
You are complaining about the management. Why?
IMO, management has done a fabulous job. Did LP make Merck pit against BMS? I think she did. Around the same time, NWBO struck a collaboration trial deal with Merck on colorectal cancer in the meantime LP had another collaboration trial with BMS on a much tougher target rGBM. I bet Merck must have worked very hard to scuttle the BMS trial.
Anyone who questions LP's leadership should read the ASCO presentation again and again. Are these results amazing? With very limited resources and under constant suppression from dark forces, NWBO was able to file the approval package and tackle very challenging issues such as isolating DCs while keeping them intact. Have you seen any other OTC company which was able to survive for such a long time and reach one milestone after another? If you cannot answer, I can answer it for you. It is a big NO!
So what is this all about???
https://nwbio.com/notice-of-settlement/
You are just a POS. He sold timely. Wait 3 months. Stock won’t change price and he will make money. You will still be here being a jack wagon 🤡
I wish the German Col the best in what he's purchased with proceeds from the NWBO he's sold, but I believe that it's what he retained that will make him the greater gain, and it won't be much longer.
I got to thinking about all the people I've suggested NWBO to who bought, I really don't know how many shares each one purchased, but I'm certain the total holdings on my part and those who've joined me is well in excess of half a million, but I don't know how close we could be to the one million mark.
I really don't believe the UK regulators will wait for the entire 150 day period, but while reliable posters don't believe an RFI came in, I don't think we can be absolutely certain. I think we can be certain the company wouldn't PR an RFI. If I'm right we have less than a month before we know.
For anyone who also looks at I-V, I'm happy to say it's back up and hope they can keep it that way. Most there are shorts, but largely intelligent ones, and some I respect, even if we don't agree, but we do have some longs there as well.
Gary
I get your point. He obviously felt like venting, as this has been a long wait under perpetual collusive manipulation.
Not a bad thing to diversify one's spec plays. Though, he'll be kicking himself if approval, or partnership, comes sooner than later.
Paid bashers are rather easy to spot... they post untruths multiple times daily. Do you know anyone like that?
If you look back, I liked his post. Probably many of them. But now he is here advertising his sale to buy elsewhere, that tells me he has lost confidence.
Does it tell you something else?
Does anyone here (other than shorts) benefit from that?
"I just didn't publicize it"
Exactly. Doesn't help any long to advertise this nonsense at this stage of the process.
Agree GermanCol is a genuine guy and has been here long time
In fact they are so confident in their plans that they don’t even care about the yearly stock swings!
CrashOverride, Ready.
Last year was tough. Mining equipment hit rock bottom. The outlook for fluorescent tubing was dim. NWBO’s stock price saw continued manipulation. For those in raisins, the market dried up. All this, while diapers remained unchanged, and every single day toilet paper touched new bottoms.
But everything is about to change. Escalators are on a steady incline. Elevators should follow and go up. Helium is rising on light trading. DCVax-L gets MHRA approval anytime now. That introduces “vaccine” into the cancer drug world. It also makes history and takes today’s cancer therapy into the 21st century real world. The nature of the doctor-patient-cancer-therapy relationship is about to change from managing toxicity to optimizing for curing cancer.
This begs the question, what happens when an unstoppable force (DCVax) meets an unmovable object (Shorts)? Shorts cover and provide fuel for the expansion of DCVax. Shorts become a blip. Retail doesn't look back.
GermanCol sample contribution: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173939247 Let's see what the stone thrower has done, if this is some short's work in response to Ex's B.S.? You know, just to keep it real.
Well it’s one of the problems of this board that if you are not a disciple, you are a nefarious short/basher .
Thank you for the reality check GoodGuy… nerves are understandably frayed but a few more weeks or pennies should not blur the clear destination of this company! GLTA
Norisk... I don't think you're correct on German Colonel being short. That's my personal opinion, but likely the opinion of a good many others here.
no, we are encouraging and supporting people who own stock and have contributed significantly to this board with their expertise for years,
It's a free world. He gave his reason... to make an investment elsewhere and needed the funds.
I did the same with another biotech I was large in. Decided to sell half of it and invest in nwbo. I just didn't publicize it.
He's still an nwbo shareholder. I don't see a problem. He hasn't been a mindless basher. On the contrary... a sensible and valuable contributor.
No risk: I didn’t encourage anyone to sell. GC obviously did that prior to my post. I just encouraged him to insult a stupid poster!! Get with the program.
Too much conspiracy theory garbage put out there, and everyone is getting brainwashed to not believe anything, imo.
GC is a straight shooter and shared his personal decision with us, that’s all.
GC is a solid member of this board and has his reasons for his decision, and all the right in the world to act on it. He kept what nwbo he felt he could in order to not miss out completely if approval and other good things happen in the meantime.
I’ve been in the same situation with other stock’s multiple times.
Imo, no bad or false intent, just competing needs and investments.
GLTA!!!
Or... perhaps management knows what they have and are so confident in their plans that they do not care about the daily stock swings, knowing the true value of the company WILL eventually be accurately reflected in its stock. Management has way more to lose than you and I, for sure.
This point is particularly true given where NWBO is in commercializing the dcvax platform: ALL HANDS ON DECK TO GET APPROVAL, FLASKWORKS AUTOMATION, PARTNERSHIPS, ADDITIONAL TRIALS, ETC.
Even a broken clock is accurate 2 times per day.
Newman- I think the idea here is that nwbo cross licenses with Oncovir everywhere which I’ll call the master license.
BP that wants to combo their drug would take a license on the master for trials thru commercialization.
For GBM, we have the master license in place- Merck would still need to use the master license so it’s the same financial relationship.
Next, the master licensees May wish to leverage sales and marketing of BP and BP wishes same so contracts would spell this out.
That’s what this looks like starting in the UK and expands as additional RA approvals are granted in other jurisdictions for GBM and later for other cancer indications.
So the franchise concept stays intact no matter the jurisdictions with approvals.
Eden’s units would be another license contract, Advent licenses the units from nwbo as would CRL in the US should Advent not expand into the US. It’s not clear if BP would license Eden’s but it’s possible.
So yes there’s a lot of licensing and cross licensing but the franchise model applies in the UK and Europe.
Last, Oncovir needs the platform no matter what- nwbo heeds Hiltonol for the benefit of the patient. That’s why I think when LP says in- licensing that likely refers especially to Oncovir as they have nothing without L and Oncovir would pay something up front and ongoing to enter the master license.
So we are encouraging posters who sell nwbo and buy other stocks?
That doesn't help anyone long nwbo.
GermanCol- your English is sufficient for effective insults at least!
Just sayin. LC is right, I don’t know.
The last paragraph first: copy n paste:
“Merck has become dependent on Keytruda for more than 40% of company sales and faces a revenue hit when Keytruda’s main U.S. patent expires in 2028.”
12:29 PM EDT, April 25, 2024 (Benzinga Newswire)
On Thursday, US drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion.
Excluding the impact of foreign exchange, sales increased 24%.
Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88.
Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y.
Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease.
Merck’s blockbuster cancer immunotherapy Keytruda largely drove the growth. Keytruda generated $6.95 billion in revenue during the quarter, up 20% from the year-earlier period.
Merck has become dependent on Keytruda for more than 40% of company sales and faces a revenue hit when Keytruda’s main U.S. patent expires in 2028.”….
UK Sawston facility Advent will make the vaccines for the whole Europe I guess. Everywhere else specifically, USA, would be Franchise; does it make sense? Ask BMY. Looks like FW is a huge success.
Thank you Dstock.
Appreciate your reply.
It saddens my heart to hear a 13 old girl having such a terrible disease. The RA needs to cut the red tape and makes this treatment available the patients ASAP.
Thank you for sharing this. Will share this with my wife.
Yes I saw NCI and when I see NCI it’s nothing but good- they have something like 100 cancer treatment centers across the US.
However, Crystal Mackall is a hero-would be a nice addition to team nwbo.
Side story- working on the driver today with an instructor who I just learned his 13 YO daughter has a grade 3 brain cancer, a subset of GBM. She’s doing well after surgery and entering 2nd round of chemo mid May. Sweet young man that needs positive thought for his family and daughter- put in a good word for Mike and his family they need it and appreciated.
50:1 reverse split?
Also this RevImmune nonsense has been around forever. But I could see a crushing reverse merge where everything goes away with a fresh start.
"The mere thought of kicking someone when they're most vulnerable,"
help me out here, he sold NWBO to buy another stock, what about this situation for him is 'vulnerable'
this strikes me as nothing but another win for shorts trying to spook out weak hands...
Thanks for your kind words and your advice ilovetech!! Appreciate it
Followers
|
1619
|
Posters
|
|
Posts (Today)
|
9
|
Posts (Total)
|
687266
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |